Inovio

521 articles with Inovio

• INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023

  2/15/2023

  INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter 2022 financial results will be released after the market close on March 1, 2023.

• INOVIO Reports Inducement Grants Under Inducement Plan

  2/3/2023

  INOVIO today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan.

• INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)

  2/2/2023

  INOVIO today announced positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo.

• INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates

  1/31/2023

  INOVIO announced a strategic reorganization that is intended to deliver on commitments to operational efficiency and better position the company to bring the promise of DNA medicines to patients.

• INOVIO Provides an Update on Lassa Fever and MERS Programs

  11/17/2022

  INOVIO announced that it has agreed with its collaborator, the Coalition for Epidemic Preparedness Innovations, to discontinue development of product candidates targeting Lassa Fever and Middle East Respiratory Syndrome, following initial analyses of data from studies conducted by INOVIO and funded by CEPI.

• INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800

  10/27/2022

  INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine.

• INOVIO to Report Third Quarter 2022 Financial Results on November 8, 2022

  10/25/2022

  INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, announced today that third quarter 2022 financial results will be released after the market close on November 8, 2022 .

• INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

  10/13/2022

  INOVIO today announced positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.

• INOVIO Reports Inducement Grants Under Inducement Plan - Sep 01, 2022

  9/1/2022

  INOVIO announced that it has made equity grants to two newly hired employees, including a Vice President of Clinical Development, under its 2022 Inducement Plan.

• INOVIO to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  8/30/2022

  INOVIO today announced that Jacqueline Shea , Ph.D., President and CEO, will present at the H.C. Wainwright 24th Annual Global Conference.

• INOVIO Reports Financial Results and Highlights for the Second Quarter 2022

  8/9/2022

  INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today reported financial results for the quarter and six months ended June 30, 2022. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Daylight Time (EDT) today to discuss financial results and provide a general business update for the second quarter.

• INOVIO to Report Second Quarter 2022 Financial Results on August 9, 2022

  7/26/2022

  INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, announced today that second quarter 2022 financial results will be released after the market close on August 9, 2022.

• INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 01, 2022

  7/1/2022

  INOVIO announced that in connection with the hiring of Dr. Michael John Sumner as Chief Medical Officer, announced on June 27, 2022, the Compensation Committee of INOVIO's Board of Directors approved equity grants to Dr. Sumner as inducement awards under INOVIO's 2022 Inducement Plan.

• INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

  6/27/2022

  INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO).

• INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022

  5/27/2022

  INOVIO's DNA medicines immunotherapy in combination with Libtayo ® elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients.

• INOVIO to Present at Jefferies 2022 Healthcare Conference

  5/23/2022

  INOVIO  today announced that Jacqueline Shea , Ph .D., President and CEO, and Jeffrey Skolnik , M .D., SVP of Clinical Development for Oncology and HPV Therapeutics, are scheduled to participate in a fireside chat and 1x1 investor meetings at the Jefferies 2022 Healthcare Conference on Wednesday, June 8th, 2022 at 1:00 PM EDT.

• INOVIO Reports First Quarter 2022 Financial Results and Program Developments

  5/10/2022

  INOVIO reported financial results for the quarter ended March 31, 2022 and announced recent program and corporate developments.

• INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer

  5/10/2022

  INOVIO announced the appointment of Jacqueline Shea, Ph.D., as President and Chief Executive Officer of INOVIO, effective immediately.

• INOVIO to Report First Quarter 2022 Financial Results on May 10, 2022

  4/26/2022

  INOVIO (NASDAQ: INO) announced today that first quarter 2022 financial results will be released after the market close on May 10, 2022.

• INOVIO to Present at Oppenheimer's 32nd Annual Healthcare Conference

  3/8/2022

  INOVIO announced that Dr. J. Joseph Kim, President and CEO, will participate in a fireside chat and 1x1 investor meetings at Oppenheimer's 32nd Annual Healthcare Conference on Tuesday, March 15, 2021.